down arrow

Neumora Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6409791000
USD
1.75
0.03 (1.74%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.711.78

52 Week

0.6111.57
Valuation
Technical
Day's Volume

CASH

1.27 M

Shareholding (Mar 2025)

FII

18.61%

Held by 68 FIIs

DII

53.06%

Held by 23 DIIs

Promoter

14.63%

How big is Neumora Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Neumora Therapeutics, Inc. has a market capitalization of 128.27 million, with net sales of 0.00 million and a net profit of -258.06 million over the latest four quarters. The company reported shareholder's funds of 287.06 million and total assets of 316.97 million as of Dec 24.

Market Cap: As of Jun 18, Neumora Therapeutics, Inc. has a market capitalization of 128.27 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Neumora Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -258.06 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 287.06 million and total assets of 316.97 million.

Read More

What does Neumora Therapeutics, Inc. do?

22-Jun-2025

Neumora Therapeutics, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $68 million and a market cap of $128.27 million. Key financial metrics include a negative P/E ratio, a debt-to-equity ratio of -1.09, and a return on equity of -113%.

Overview: <BR>Neumora Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -68 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 128.27 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.09 <BR>Return on Equity: -113.00% <BR>Price to Book: 0.56<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Neumora Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Neumora Therapeutics, Inc. exhibits a mildly bearish technical trend, with daily moving averages bearish and mixed signals from other indicators, significantly underperforming the S&P 500 with year-to-date and one-year returns of -85.19% and -87.14%, respectively.

As of 8 September 2025, the technical trend for Neumora Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows no signal. The Bollinger Bands suggest a mildly bullish outlook on the weekly chart but are bearish on the monthly. Daily moving averages are bearish, and the KST is bullish on the weekly but shows no trend monthly. The Dow Theory reflects a mildly bullish trend weekly with no trend monthly, while the OBV is mildly bearish across both time frames.<BR><BR>The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -85.19% versus the S&P 500's 12.22%, and a one-year return of -87.14% compared to 17.14% for the benchmark. Overall, the technical stance is mildly bearish, driven by the bearish daily moving averages and mixed signals from other indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 269 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.08

stock-summary
Return on Equity

-137.84%

stock-summary
Price to Book

1.47

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-53 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.57%
0%
-0.57%
6 Months
124.36%
0%
124.36%
1 Year
-83.33%
0%
-83.33%
2 Years
-87.97%
0%
-87.97%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Neumora Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-62.02%
EBIT to Interest (avg)
-205.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.09
Sales to Capital Employed (avg)
34.92
Tax Ratio
0.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
58.44%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.72
EV to EBIT
0.31
EV to EBITDA
0.31
EV to Capital Employed
3.98
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1290.10%
ROE (Latest)
-113.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 37 Schemes (13.7%)

Foreign Institutions

Held by 68 Foreign Institutions (18.61%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 10.22% vs -52.47% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.00",
          "val2": "-63.70",
          "chgp": "15.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-52.70",
          "val2": "-58.70",
          "chgp": "10.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -3.35% vs -80.21% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-262.80",
          "val2": "-187.50",
          "chgp": "-40.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-63.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-243.80",
          "val2": "-235.90",
          "chgp": "-3.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-54.00
-63.70
15.23%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-52.70
-58.70
10.22%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 10.22% vs -52.47% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-262.80
-187.50
-40.16%
Interest
0.00
0.00
Exceptional Items
0.00
-63.90
100.00%
Consolidate Net Profit
-243.80
-235.90
-3.35%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -3.35% vs -80.21% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Neumora Therapeutics, Inc. stock-summary
stock-summary
Neumora Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."